Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents Export

@article{citeulike:5027274, abstract = {Diabetes mellitus (DM) is a metabolic disorder that requires medical diagnosis and treatment. Type 2 DM is due to a combination of defective secretion of and responsiveness to insulin. In early stages, the predominant abnormality is reduced insulin sensitivity, and hyperglycemia can be reversed by a variety of measures and medications. In this stage, the cornerstone of glucose-lowering therapy is lifestyle modification, but when counseling does not adequately achieve the recommended glycemic targets, at least five classes of oral drugs are available. In general, α-glucosidase inhibitors delay carbohydrate absorption, metiglinides and sulfonylureas increase insulin supply, and biguanides and thiazolidinediones enhance insulin action. Given the high cardiovascular morbidity and mortality in type 2 DM patients, the attempt to reduce cardiovascular complications, beyond the glucose lowering itself, is an extremely relevant task. Indeed, the role of oral glucose-lowering agents concerning hyperglycemia reduction is defined; however, they have not clearly demonstrated to reduce micro- and macrovascular disease, and hitherto, no firm evidence favors one pharmacological treatment over another. The aim of this update is to describe the existing experiences with oral glucose-lowering agents for type 2 DM treatment with respect to cardiovascular prevention.}, author = {Anselmino, Matteo}, citeulike-article-id = {5027274}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.jdiacomp.2008.07.003}, citeulike-linkout-1 = {http://linkinghub.elsevier.com/retrieve/pii/S105687270800072X}, day = {02}, doi = {10.1016/j.jdiacomp.2008.07.003}, issn = {10568727}, journal = {Journal of Diabetes and its Complications}, keywords = {hyperglycaemia}, month = {November}, number = {6}, pages = {427--433}, posted-at = {2009-11-01 22:32:03}, priority = {2}, title = {Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents}, url = {http://dx.doi.org/10.1016/j.jdiacomp.2008.07.003}, volume = {23}, year = {2009} }

TY - JOUR ID - citeulike:5027274 L3 - citeulike-article-id:5027274 N2 - Diabetes mellitus (DM) is a metabolic disorder that requires medical diagnosis and treatment. Type 2 DM is due to a combination of defective secretion of and responsiveness to insulin. In early stages, the predominant abnormality is reduced insulin sensitivity, and hyperglycemia can be reversed by a variety of measures and medications. In this stage, the cornerstone of glucose-lowering therapy is lifestyle modification, but when counseling does not adequately achieve the recommended glycemic targets, at least five classes of oral drugs are available. In general, α-glucosidase inhibitors delay carbohydrate absorption, metiglinides and sulfonylureas increase insulin supply, and biguanides and thiazolidinediones enhance insulin action. Given the high cardiovascular morbidity and mortality in type 2 DM patients, the attempt to reduce cardiovascular complications, beyond the glucose lowering itself, is an extremely relevant task. Indeed, the role of oral glucose-lowering agents concerning hyperglycemia reduction is defined; however, they have not clearly demonstrated to reduce micro- and macrovascular disease, and hitherto, no firm evidence favors one pharmacological treatment over another. The aim of this update is to describe the existing experiences with oral glucose-lowering agents for type 2 DM treatment with respect to cardiovascular prevention. IS - 6 JF - Journal of Diabetes and its Complications SN - 10568727 EP - 433 TI - Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents VL - 23 SP - 427 KW - hyperglycaemia AU - Anselmino, Matteo PY - 2009/11/02/ UR - http://dx.doi.org/10.1016/j.jdiacomp.2008.07.003 ER -